Frits Van Rhee, MD, PhD, MRCP

Research Program: Cancer Therapeutics Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Medicine

Cancer Research Interest

• Disease Site Focus: Multiple Myeloma
• Research Focus Area: Treatment, Diagnosis/ Prognosis
• Type of Research: Clinical, Basic

Contact Information

• Email Address: VANRHEEFRITS@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody” (NCT03763370)
• “Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma” (NCT05346835)
• “M22-947: A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma” (NCT05259839)
• “Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release” (NCT04771078)
• “A Phase II, Single-Arm Open-Label Multi-Center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease” (NCT03933904)

Active Grants

• NIH/Nat. Heart, Lung & Blood Institute – 2R01HL141408
  “JAK1/2 as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target ”
  Principal Investigator
  09/01/23 – 05/31/24
• NIH/Nat. Cancer Institute – 2R01CA209882
  “Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma”
  Co-Investigator
  07/01/23 – 06/30/28
• Food & Drug Administration – 1-R01-FD-007632-01
  “ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease”
  Principal Investigator
  09/15/22 – 08/31/26

Publications

• Guo W, Strouse C, Mery D, [et al., including van Rhee F]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
• Mohan M, Monge J, Shah N, [et al., including van Rhee F]. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood cancer journal. 2024 14(1):35. PMID: 38443345. PMCID: PMC10914756.
• Nishikori A, Nishimura MF, Fajgenbaum DC, [et al., including van Rhee F]. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. Journal of clinical pathology. 2024. PMID: 38378248.
• Mohan M, Szabo A, Patwari A, [et al., including van Rhee F]. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone marrow transplantation. 2024. PMID: 38361116.
• Guo W, Zhan Y, Mery D, [et al., including van Rhee F]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
• Mao X, Yan W, Mery D, [et al., including van Rhee F]. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. American journal of hematology. 2024. PMID: 38247315. PMCID: PMC10947864.
• Sun F, Cheng Y, Wanchai V, [et al., including van Rhee F]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
• Bustamante MS, Pierson SK, Ren Y, [et al., including Van Rhee F]. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease. Haematologica. 2024. PMID: 38205523.
• Garg TK, Garg S, Miousse IR, [et al., including van Rhee F]. Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body Radiation. Radiation research. 2023. PMID: 38059553.
• Al Hadidi S, Ababneh O, Schinke C, [et al., including van Rhee F]. Three Years Maintenance with VRD in Multiple Myeloma: Results of Total Therapy IIIB with a 15-Year Follow Up. Blood advances. 2023. PMID: 38052037. PMCID: PMC10845028.
• Lang E, van Rhee F. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances. Blood reviews. 2023:101161. PMID: 38087716.
• Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. The oncologist. 2023. PMID: 37995307. PMCID: PMC10911930.
• Sarmiento Bustamante M, Shyamsundar S, Coren FR, [et al., including van Rhee F]. Ongoing symptoms following complete surgical excision in unicentric Castleman disease. American journal of hematology. 2023 98(11):E334-E337. PMID: 37635628. PMCID: PMC10998479.
• Sun F, Cheng Y, Chen JR, [et al., including van Rhee F]. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. The Journal of clinical investigation. 2023. PMID: 37883186. PMCID: PMC10760955.
• Mango NA, Pierson SK, Sarmiento Bustamante M, [et al., including van Rhee F]. Siltuximab administration results in spurious IL-6 elevation in peripheral blood. American journal of hematology. 2023. PMID: 37867418. PMCID: PMC10998478.
• Cheng Y, Sun F, Alapat DV, [et al., including van Rhee F]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
• Ling W, Johnson SK, Mehdi SJ, [et al., including van Rhee F]. EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers. 2023 15(18). PMID: 37760488. PMCID: PMC10526862.
• Pierson SK, Lim MS, Srkalovic G, [et al., including van Rhee F]. Treatment Consistent with Idiopathic Multicentric Castleman Disease Guidelines is Associated with Improved Outcomes. Blood advances. 2023. PMID: 37656441. PMCID: PMC10637880.
• Hammons L, Szabo A, Janardan A, [et al., including Van Rhee F]. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023. PMID: 37646658. PMCID: PMC10905074.
• John L, Poos AM, Brobeil A, [et al., including van Rhee F]. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nature communications. 2023 14(1):5011. PMID: 37591845. PMCID: PMC10435504.
• Fahmawi S, Schinke C, Thanendrarajan S, [et al., including van Rhee F]. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. Journal of cancer policy. 2023 37:100433. PMID: 37468042.
• Mehdi SJ, Ghatak K, Ling W, [et al., including van Rhee F]. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leukemia research. 2023 133:107355. PMID: 37499483.
• Sun F, Cheng Y, Ying J, [et al., including Van Rhee F]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
• Mohan M, Gong Z, Ashby TC, [et al., including van Rhee F]. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023. PMID: 37282609.
• Abu Za'nouneh FJ, Ababneh O, Schinke C, [et al., including van Rhee F]. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 4(2):454-458. PMID: 37206288. PMCID: PMC10188470.
• Amisha F, Saluja P, Malik P, Van Rhee F. Acquired hemophilia A (AHA) due to anti-SARS-CoV-2 vaccination: A systematic review. EJHaem. 2023 4(2):532-543. PMID: 37206259. PMCID: PMC10188482.
• Mazahreh F, Mazahreh L, Schinke C, [et al., including Van Rhee F]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023. PMID: 36857755. PMCID: PMC10331406.
• Choudhury S, Byrum SD, Alkam D, [et al., including Van Rhee F]. Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clinical epigenetics. 2023 15(1):18. PMID: 36737807. PMCID: PMC9898982.
• Al Hadidi S, Dongarwar D, Schinke C, [et al., including van Rhee F]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023. PMID: 36737587. PMCID: PMC10241736.
• Al Hadidi S, van Rhee F. Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023:JCO2202098. PMID: 36626704.
• Shrivastava T, Van Rhee F, Al Hadidi S. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives. OncoTargets and therapy. 2023 16:441-464. PMID: 37359353. PMCID: PMC10290473.
• Al Hadidi S, Szabo A, Esselmann J, [et al., including van Rhee F]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2022. PMID: 36550200.
• Garg TK, Garg S, Miousse IR, [et al., including van Rhee F]. Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model. International journal of molecular sciences. 2022 23(24). PMID: 36555814. PMCID: PMC9784560.
• Ajore R, Niroula A, Pertesi M, [et al., including van Rhee F]. Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nature communications. 2022 13(1):7725. PMID: 36513657. PMCID: PMC9747780.
• Thompson MA, Boccadoro M, Leleu X, [et al., including van Rhee F]. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clinical lymphoma, myeloma & leukemia. 2022. PMID: 36641358.
• Mohan M, Rein LE, Thalambedu N, [et al., including van Rhee F]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
• Pierson SK, Katz L, Williams R, [et al., including van Rhee F]. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nature communications. 2022 13(1):7236. PMID: 36433996. PMCID: PMC9700691.
• Al Hadidi S, Dongarwar D, Salihu H, [et al., including van Rhee F]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
• van Rhee F. Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. The New England journal of medicine. 2022 387(8):762-763. PMID: 36001726.
• Schinke C, Poos AM, Bauer MA, [et al., including van Rhee F]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood advances. 2022. PMID: 35977111. PMCID: PMC9647426.
• Rasche L, Schinke C, Maura F, [et al., including van Rhee F]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
• Alqazaqi R, Schinke C, Thanendrarajan S, [et al., including van Rhee F]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
• Nishimura Y, Nishimura MF, Fajgenbaum DC, [et al., including van Rhee F]. Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis. EJHaem. 2022 3(3):748-753. PMID: 36051051. PMCID: PMC9421978.
• Gai D, Chen JR, Stewart JP, [et al., including van Rhee F]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
• van Rhee F, Rosenthal AL, Kanhai K, [et al.]. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood advances. 2022. PMID: 35793409. PMCID: PMC9631655.
• Sudha P, Ahsan A, Ashby C, [et al., including van Rhee F]. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 35522533. PMCID: PMC9250632.
• Fajgenbaum DC, Pierson SK, Kanhai K, [et al., including van Rhee F]. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. British journal of haematology. 2022. PMID: 35507638. PMCID: PMC9544190.
• Van Rhee F. Nearly 70 years later: the continued unraveling of Castleman disease. Haematologica. 2022. PMID: 35484683. PMCID: PMC9827149.
• Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA oncology. 2022. PMID: 35482363.
• Mohan M, Becnel MR, Shah UA, [et al., including van Rhee F]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022. PMID: 35472167. PMCID: PMC10476149.
• Al Hadidi S, Schinke C, Thanendrarajan S, [et al., including van Rhee F]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
• Abushukair H, Syaj S, Ababneh O, [et al., including van Rhee F]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022. PMID: 35358350.
• Larsen K, Spencer H, Mohan M, [et al., including van Rhee F]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
• Mohan M, Gundarlapalli S, Szabo A, [et al., including van Rhee F]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022. PMID: 35285981.
• Ajore R, Niroula A, Pertesi M, [et al., including van Rhee F]. Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nature communications. 2022 13(1):151. PMID: 35013207. PMCID: PMC8748989.
• Lang E, Sande B, Brodkin S, van Rhee F. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report. Therapeutic advances in hematology. 2022 13:20406207221082552. PMID: 35251585. PMCID: PMC8894931.
• Rossi JF, Chiang HC, Lu ZY, [et al., including van Rhee F]. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. Frontiers in immunology. 2022 13:919489. PMID: 35928820. PMCID: PMC9345304.
• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including van Rhee F]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
• Roy Choudhury S, Ashby C, Zhan F, van Rhee F. Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients. Cancers. 2021 13(24). PMID: 34944968. PMCID: PMC8699806.
• Baker D, Bimali M, Carrillo L, [et al., including Van Rhee F]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 106(12):3215-3218. PMID: 34847659. PMCID: PMC8634177.
• Mohan M, Kendrick S, Szabo A, [et al., including van Rhee F]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986. PMCID: PMC8945288.
• Pierson SK, Shenoy S, Oromendia AB, [et al., including van Rhee F]. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood advances. 2021 5(17):3445-3456. PMID: 34438448. PMCID: PMC8525223.
• Baker D, Bimali M, Carrillo L, [et al., including Van Rhee F]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021. PMID: 34382384.
• Yarlagadda L, Boerma M, Gundarlapalli S, [et al., including van Rhee F]. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 13(16). PMID: 34439174. PMCID: PMC8392190.
• Boyle EM, Rosenthal A, Ghamlouch H, [et al., including van Rhee F]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
• Biran N, Dhakal B, Lentzsch S, [et al., including van Rhee F]. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem. 2021 2(3):375-384. PMID: 35844693. PMCID: PMC9175784.
• Nishimura Y, Fajgenbaum DC, Pierson SK, [et al., including van Rhee F]. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. American journal of hematology. 2021. PMID: 34265103. PMCID: PMC9642098.
• Boyle EM, Rosenthal A, Wang Y, [et al., including van Rhee F]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
• Mohan M, Meek JC, Meek ME, [et al., including van Rhee F]. Combinatorial treatment for unresectable unicentric Castleman disease. European journal of haematology. 2021. PMID: 34242421.
• Hájek R, Minařík J, Straub J, [et al., including van Rhee F]. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future oncology (London, England). 2021 17(19):2499-2512. PMID: 33769076.
• Li C, Xia J, Franqui Machin R, [et al., including van Rhee F]. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. The Journal of clinical investigation. 2021. PMID: 34061780. PMCID: PMC8279583.
• Mohan M, Szabo A, Yarlagadda N, [et al., including van Rhee F]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
• Schinke CD, Boerma M, Bird JT, [et al., including van Rhee F]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.
• Mitma AA, Burgess MJ, van Rhee F. Ehrlichia-induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant. Transplant infectious disease : an official journal of the Transplantation Society. 2021:e13621. PMID: 33877729.
• Mohan M, Tackett A, Kumar M, [et al., including van Rhee F]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629. PMCID: PMC8627246.
• Landau HJ, Yellapantula V, Diamond BT, [et al., including van Rhee F]. Author Correction: Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2021 12(1):591. PMID: 33473129. PMCID: PMC7817844.
• Boyle EM, Deshpande S, Tytarenko R, [et al., including van Rhee F]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579. PMCID: PMC7804406.
• Pierson SK, Khor JS, Ziglar J, [et al., including van Rhee F]. ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell reports. Medicine. 2020 1(9):100158. PMID: 33377129. PMCID: PMC7762771.
• van Rhee F, Oksenhendler E, Srkalovic G, [et al.]. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood advances. 2020 4(23):6039-6050. PMID: 33284946. PMCID: PMC7724917.
• Danziger SA, McConnell M, Gockley J, [et al., including van Rhee F]. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine. 2020 17(11):e1003323. PMID: 33147277. PMCID: PMC7641353.
• van Rhee F, Rossi JF, Simpson D, [et al.]. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. British journal of haematology. 2020. PMID: 33128769. PMCID: PMC7820993.
• Deshpande S, Tytarenko RG, Wang Y, [et al., including van Rhee F]. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European journal of haematology. 2020. PMID: 33107092.
• Fajgenbaum DC, Wu D, Goodman A, [et al., including van Rhee F]. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American journal of hematology. 2020. PMID: 32894785. PMCID: PMC9547644.
• Dhodapkar MV, Sexton R, Hoering A, [et al., including Van Rhee F]. Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 32816893. PMCID: PMC7679008.
• Choudhury SR, Ashby C, Tytarenko R, [et al., including van Rhee F]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
• Landau HJ, Yellapantula V, Diamond BT, [et al., including van Rhee F]. Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 11(1):3617. PMID: 32680998. PMCID: PMC7368016.
• Schinke C, Boyle EM, Ashby C, [et al., including van Rhee F]. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 10(6):70. PMID: 32555163. PMCID: PMC7303180.
• Pai RL, Japp AS, Gonzalez M, [et al., including van Rhee F]. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI insight. 2020 5(9). PMID: 32376796. PMCID: PMC7253017.
• Mohan M, Weinhold N, Schinke C, [et al., including van Rhee F]. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British journal of haematology. 2020 189(1):67-71. PMID: 31820442.
• van Rhee F, Casper C, Voorhees PM, [et al.]. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. The Lancet. Haematology. 2020 7(3):e209-e217. PMID: 32027862.
• Nishimura KK, Barlogie B, van Rhee F, [et al.]. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood advances. 2020 4(2):422-431. PMID: 31990333. PMCID: PMC6988393.
• Boyle EM, Ashby C, Tytarenko R, [et al., including van Rhee F]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
• Du Z, Weinhold N, Song GC, [et al., including Van Rhee F]. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood advances. 2020 4(1):181-190. PMID: 31935283. PMCID: PMC6960456.
• Russell SJ, Babovic-Vuksanovic D, Bexon A, [et al., including Van Rhee F]. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic proceedings. 2019 94(9):1834-1839. PMID: 31235278. PMCID: PMC6800178.
• Fajgenbaum DC, Langan RA, Japp AS, [et al., including van Rhee F]. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. The Journal of clinical investigation. 2019 129(10):4451-4463. PMID: 31408438. PMCID: PMC6763254.
• Sawyer JR, Tian E, Walker BA, [et al., including van Rhee F]. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood cancer journal. 2019 9(8):62. PMID: 31399558. PMCID: PMC6689064.
• Rasche L, Alapat D, Kumar M, [et al., including van Rhee F]. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 33(7):1713-1722. PMID: 30573775. PMCID: PMC6586541.